CDK4 and non-small cell lung carcinoma: It should be emphasized that fascaplysin demonstrates significant anticancer activity in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) lines, which is not depending on the CDK4 pathway suggesting the direct effects on the DNA function and transcription of various proteins [59].